Nektar Therapeutics: basic earnings per share
Basic earnings per share for Nektar Therapeutics. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Nektar Therapeutics financial histories
What this measure means
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -9.73 | USD/shares | 2026-03-13 | 10-K · 0001193125-26-104547 |
| 2024-01-01 | 2024-12-31 | -8.68 | USD/shares | 2026-03-13 | 10-K · 0001193125-26-104547 |
| 2023-01-01 | 2023-12-31 | -1.45 | USD/shares | 2025-03-14 | 10-K · 0000950170-25-039389 |
| 2022-01-01 | 2022-12-31 | -1.97 | USD/shares | 2024-03-05 | 10-K · 0000950170-24-026249 |
| 2021-01-01 | 2021-12-31 | -2.86 | USD/shares | 2024-03-05 | 10-K · 0000950170-24-026249 |
| 2020-01-01 | 2020-12-31 | -2.49 | USD/shares | 2023-02-28 | 10-K · 0000906709-23-000004 |
| 2019-01-01 | 2019-12-31 | -2.52 | USD/shares | 2022-03-01 | 10-K · 0000906709-22-000005 |
| 2018-01-01 | 2018-12-31 | 4.02 | USD/shares | 2021-02-26 | 10-K · 0000906709-21-000005 |
| 2017-01-01 | 2017-12-31 | -0.62 | USD/shares | 2020-02-28 | 10-K · 0000906709-20-000004 |
| 2016-01-01 | 2016-12-31 | -1.1 | USD/shares | 2019-03-01 | 10-K · 0001564590-19-005639 |
Related financial histories
- Nektar Therapeutics: total assets
- Nektar Therapeutics: total liabilities
- Nektar Therapeutics: stockholders equity
- Nektar Therapeutics: cash and cash equivalents
- Nektar Therapeutics: net income or loss
- Nektar Therapeutics: operating cash flow
- Nektar Therapeutics: capital expenditure payments
- Nektar Therapeutics: revenue
- Nektar Therapeutics: contract revenue excluding tax
- Nektar Therapeutics: financing cash flow
- Nektar Therapeutics: investing cash flow
- Nektar Therapeutics: retained earnings or deficit
- Nektar Therapeutics: basic weighted-average shares
- Nektar Therapeutics: diluted weighted-average shares
- Nektar Therapeutics: diluted earnings per share
- Nektar Therapeutics: income tax expense or benefit
- Nektar Therapeutics: net property, plant and equipment
- Nektar Therapeutics: share-based compensation expense
- Nektar Therapeutics: operating income or loss
- Nektar Therapeutics: current assets
- Nektar Therapeutics: interest expense
- Nektar Therapeutics: current liabilities
- Nektar Therapeutics: current accounts payable
- Nektar Therapeutics: goodwill carrying amount
- Nektar Therapeutics: net current accounts receivable
- Nektar Therapeutics: common-stock repurchase payments
- Nektar Therapeutics: net inventory
- Nektar Therapeutics: research and development expense
Inspect the source
- Entity
- Nektar Therapeutics / CIK 0000906709
- Captured
- 2026-09-20T05:05:37.584Z
- SEC response SHA-256
e2600c46c7f668543c6f872627f345bdb6f22832099c13decf2fa4b7a0e4aabe
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000906709.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))